Jun 2026 (Q2 FY26) — Aug 4, 2026
Arvinas Q2 FY26 — VEPPANU Approval & Pipeline Advancement
Read the full callArvinas (ARVN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Arvinas earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 250 | +1014.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 65.7 | +384.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 169 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.16 +4.99% · +$0.34
Performance −23.9% 1Y
1Y: $9.41 on 14 Oct 2025 → $7.16. High $13.83 (2 Feb 2026), low $6.82 (14 Oct 2026).
- Previous close
- $6.82
- 52-week range
- $6.82 – $13.83
- One year
- −24.31%
Overview
- Symbol
- ARVN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Arvinas earnings calls (ARVN)
Financials
What the filings say
Net profit, year on year: +377% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 59 | 189 | 22 | 42 | 10 | 16 | 250 |
| Operating profit | -60 | -58 | 71 | -71 | -44 | -75 | -64 | 164 |
| Operating margin | −58.9% | −98.1% | 37.8% | −319.2% | −104.5% | −785.3% | −409.0% | 65.7% |
| Other income | 12 | 13 | 12 | 10 | 9 | 7 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | — | — | — | — |
| Profit before tax | -49 | -45 | 83 | -61 | -35 | -67 | -57 | 170 |
| Tax rate | −1.2% | 0.7% | 0.2% | 0.5% | −0.9% | −0.1% | −0.2% | 0.1% |
| Net profit | -49 | -45 | 83 | -61 | -35 | -67 | -58 | 169 |
| EPS ($ per share) | -0.68 | — | 1.14 | -0.84 | -0.48 | — | -0.90 | 2.61 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -302 | -373 | -492 | -683 | -965 | -1,333 | -1,532 | -1,612 |
| Total liabilities | 63 | 75 | 75 | 800 | 704 | 645 | 530 | 284 |
| Fixed assets | 4 | 8 | 12 | 13 | 13 | 12 | 7 | 5 |
| Investments | 185 | 272 | 100 | 1,394 | 1,124 | 949 | 939 | 543 |
| Total assets | 199 | 302 | 717 | 1,582 | 1,269 | 1,305 | 1,091 | 718 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -16 | -41 | -90 | 559 | -273 | -348 | -259 | -274 |
| Cash from investing | -180 | -93 | 164 | -1,314 | 243 | 204 | 35 | 408 |
| Cash from financing | 168 | 140 | 505 | 279 | 5 | 375 | 8 | -91 |
| Net cash flow | -28 | 6 | 579 | -476 | -26 | 230 | -217 | 42 |
| Capital expenditure | -3 | -6 | -6 | -5 | -7 | -3 | -2 | -2 |
| Free cash flow | -19 | -47 | -96 | 555 | -280 | -351 | -261 | -276 |
Insider filings
35 filings between Nov 7, 2025 and Jun 24, 2026.
Open market
decisions to buy or sellPurchases
$268.1K
1 purchase by 1 insider
Sales
$1.42M
23 sales by 6 insiders
9% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Houston John G | — | $466.2K | Feb 27, 2026 |
| Morrison Briggs | $268.1K | — | Mar 6, 2026 |
| Berkowitz Noah | — | $249.4K | May 11, 2026 |
| Teel Randy | — | $226.5K | May 21, 2026 |
| Saik Andrew | — | $218.2K | Jun 24, 2026 |
| Cacace Angela M | — | $214.0K | Jun 17, 2026 |
| Loomis David K | — | $46.9K | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 24, 2026 | Cunningham Everett Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Kennedy Edward Moore Jr. Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Morrison Briggs Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Norwalk Leslie V Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Bain Linda Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Smaldone Alsup Laurie Director | Award | 15,527 | $0 |
| Jun 24, 2026 | Saik Andrew Chief Financial Officer | Sale 10b5-1 plan | 5,696 | $46.5K |
| Jun 17, 2026 | Cacace Angela M Chief Scientific Officer | Sale 10b5-1 plan | 2,576 | $19.6K |
| May 21, 2026 | Teel Randy President and CEO | Sale | 2,209 | $20.0K |
| May 11, 2026 | Teel Randy President and CEO | Sale | 9,657 | $96.0K |
| May 11, 2026 | Berkowitz Noah Chief Medical Officer | Sale | 11,108 | $110.4K |
| May 11, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 9,657 | $96.0K |
| May 11, 2026 | Loomis David K VP, Chief Accounting Officer | Sale | 1,919 | $19.1K |
| May 11, 2026 | Saik Andrew Chief Financial Officer | Sale | 11,139 | $110.7K |
| Mar 18, 2026 | Berkowitz Noah Chief Medical Officer | Sale | 6,435 | $71.4K |
| Mar 6, 2026 | Morrison Briggs Director | Purchase | 20,000 | $268.1K |
| Feb 27, 2026 | Houston John G Director | Sale | 4,688 | $62.1K |
| Feb 27, 2026 | Houston John G Director | Sale | 18,822 | $249.2K |
| Feb 27, 2026 | Houston John G Director | Sale | 11,787 | $154.9K |
| Feb 26, 2026 | Teel Randy President and CEO | Award | 147,179 | $0 |
| Feb 26, 2026 | Cacace Angela M Chief Scientific Officer | Award | 45,000 | $0 |
| Feb 26, 2026 | Saik Andrew Chief Financial Officer | Award | 45,000 | $0 |
| Feb 26, 2026 | Berkowitz Noah Chief Medical Officer | Award | 45,000 | $0 |
| Feb 26, 2026 | Loomis David K VP, Chief Accounting Officer | Award | 12,420 | $0 |
| Feb 23, 2026 | Teel Randy President and CEO | Sale | 1,038 | $12.6K |
| Feb 23, 2026 | Teel Randy President and CEO | Sale | 3,748 | $45.6K |
| Feb 23, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 1,038 | $12.6K |
| Feb 23, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 2,571 | $31.3K |
| Feb 23, 2026 | Loomis David K Chief Accounting Officer | Sale | 1,108 | $13.5K |
| Feb 13, 2026 | Teel Randy President and CEO | Sale | 4,403 | $52.4K |
| Feb 13, 2026 | Loomis David K Chief Accounting Officer | Sale | 1,016 | $12.1K |
| Feb 13, 2026 | Berkowitz Noah Chief Medical Officer | Sale | 5,685 | $67.6K |
| Feb 13, 2026 | Cacace Angela M Chief Scientific Officer | Sale | 4,592 | $54.6K |
| Feb 13, 2026 | Saik Andrew Chief Financial Officer | Sale | 5,134 | $61.0K |
| Nov 7, 2025 | Loomis David K Chief Accounting Officer | Sale | 230 | $2.3K |
| Sep 22, 2025 | Morrison Briggs Director | Purchase | 30,000 | $227.0K |
| Jun 25, 2025 | AGARWAL SUNIL Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Norwalk Leslie V Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Cunningham Everett Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Kennedy Edward Moore Jr. Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Bain Linda Director | Award | 16,025 | $0 |
| Jun 25, 2025 | YOUNG JOHN D Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Morrison Briggs Director | Award | 16,025 | $0 |
| Jun 25, 2025 | Smaldone Alsup Laurie Director | Award | 16,025 | $0 |
| Jun 24, 2025 | Saik Andrew Chief Financial Officer | Sale | 5,700 | $43.4K |
| Jun 17, 2025 | Cacace Angela M Chief Scientific Officer | Sale | 2,583 | $19.3K |
| May 9, 2025 | Berkowitz Noah Chief Medical Officer | Award | 59,600 | $0 |
| May 9, 2025 | Cacace Angela M Chief Scientific Officer | Award | 59,600 | $0 |
| May 9, 2025 | Saik Andrew Chief Financial Officer | Award | 59,600 | $0 |
| May 9, 2025 | Loomis David K Chief Accounting Officer | Award | 11,825 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ARVINAS, INC.
Free account. Everything above stays public.
Write why you follow ARVINAS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading